
(S)-(+)-Ibuprofen
Overview
Description
(S)-(+)-Ibuprofen, also known as dexibuprofen, is the pharmacologically active enantiomer of racemic ibuprofen, a non-steroidal anti-inflammatory drug (NSAID). It inhibits cyclooxygenase (COX) enzymes, particularly COX-2 (IC50 = 1.1 μM), with higher potency than COX-1 (IC50 = 2.9 μM) . Unlike the racemic mixture, which contains equal parts (R)-(-)- and this compound, the (S)-enantiomer is solely responsible for therapeutic effects due to its stereospecific binding to COX . Approximately 50–60% of the (R)-enantiomer undergoes metabolic inversion to this compound via 2-arylpropionyl-CoA epimerase in vivo, explaining the efficacy of racemic formulations . This compound is commercially available in tablets, gels, and intravenous formulations, with doses typically 25–50% lower than racemic equivalents for comparable efficacy .
Preparation Methods
Synthetic Routes and Reaction Conditions
The preparation of dexibuprofen involves the resolution of racemic ibuprofen into its enantiomers. One method includes adding toluene into a reaction kettle, followed by ibuprofen and meglumine, heating to 76-80°C, and maintaining the temperature for over 0.5 hours. The material is then transferred into an amine salt crystallization kettle, followed by the addition of purified water, cooling for crystallization, and performing centrifugal separation, washing, and drying to obtain dexibuprofen meglumine salt .
Industrial Production Methods
Industrial production of dexibuprofen can involve the use of nanotechnology. For instance, dexibuprofen nanocrystals can be fabricated using a microchannel fluidic reactor. This method involves mixing drug and polymer solutions in the reactor, followed by decanting the nanosuspension into a vial containing the polymer solution. The process parameters such as inlet angle, antisolvent and solvent flow rates, mixing time, and drug concentration are optimized to produce stable nanocrystals .
Chemical Reactions Analysis
(S)-(+)-Ibuprofen undergoes various chemical reactions, including:
Oxidation: this compound can be oxidized under specific conditions, leading to the formation of various oxidation products.
Reduction: Reduction reactions can convert dexibuprofen into its reduced forms.
Substitution: this compound can undergo substitution reactions where one functional group is replaced by another. Common reagents and conditions used in these reactions include oxidizing agents like potassium permanganate, reducing agents like lithium aluminum hydride, and various catalysts. .
Scientific Research Applications
Pain Management
(S)-(+)-Ibuprofen is extensively employed for managing various types of pain, including:
- Acute Pain : Effective in treating postoperative pain and acute injuries.
- Chronic Pain : Used in conditions such as osteoarthritis and rheumatoid arthritis.
- Gout : Demonstrated efficacy in alleviating symptoms during acute gout attacks, with studies showing rapid improvement in patients treated with high doses (2400 mg) .
Anti-Inflammatory Uses
The anti-inflammatory effects of this compound are attributed to its ability to inhibit cyclooxygenase enzymes (COX-1 and COX-2), which play a crucial role in the inflammatory response. Specific applications include:
- Pericarditis : Recommended as a treatment option for acute pericarditis, showing effectiveness comparable to aspirin .
- Inflammatory Conditions : Utilized in various inflammatory disorders due to its ability to reduce prostaglandin synthesis .
Antipyretic Effects
This compound is commonly used to reduce fever. In clinical studies, it has been shown to be more effective than acetaminophen in lowering temperatures associated with infections such as uncomplicated falciparum malaria .
Cancer Treatment Potential
Recent research indicates that this compound may have anticancer properties. Studies suggest its potential role in:
- Colorectal Cancer Prevention : Some evidence supports its use in reducing the incidence of colorectal cancer .
- Chemotherapy Resistance : Investigations are ongoing regarding its ability to enhance the efficacy of chemotherapy agents by mitigating resistance mechanisms .
Neuropathic Pain Management
Research has indicated that this compound may affect endocannabinoid metabolism, potentially offering benefits in neuropathic pain settings. A study found that it inhibits the metabolism of endocannabinoids more effectively than arachidonic acid metabolism, suggesting a unique analgesic mechanism .
Adverse Reactions and Safety Profile
While generally safe when used appropriately, this compound can cause adverse reactions, including:
- Stevens-Johnson Syndrome : A rare but severe skin reaction linked to ibuprofen use has been documented .
- Liver Injury : Case studies have reported instances of drug-induced liver injury associated with ibuprofen, emphasizing the need for careful monitoring .
Comprehensive Data Table
Case Studies
Several case studies illustrate the diverse applications and implications of this compound:
- Case of Acute Gout : A study highlighted rapid symptom resolution in patients treated with high-dose ibuprofen during gout attacks, demonstrating its effectiveness as a first-line therapy .
- Stevens-Johnson Syndrome : A case involving a child who developed severe skin reactions after ibuprofen use underscores the importance of monitoring for adverse drug reactions .
- Liver Injury Case Study : Documented instances of ibuprofen-induced liver injury call attention to the need for awareness regarding potential hepatotoxicity associated with NSAIDs .
Mechanism of Action
(S)-(+)-Ibuprofen exerts its effects by inhibiting the enzyme cyclooxygenase-2 (COX-2), which is involved in the synthesis of prostaglandins. Prostaglandins are lipid compounds that play a key role in inflammation, pain, and fever. By inhibiting COX-2, dexibuprofen reduces the production of prostaglandins, leading to decreased inflammation and pain .
Comparison with Similar Compounds
Comparison with Racemic Ibuprofen
Pharmacological Activity
Parameter | (S)-(+)-Ibuprofen | Racemic Ibuprofen | References |
---|---|---|---|
COX-1 Inhibition | IC50 = 2.9 μM | IC50 = 4.5 μM* | |
COX-2 Inhibition | IC50 = 1.1 μM | IC50 = 2.3 μM* | |
Active Enantiomer | 100% | 50% (R) + 50% (S) |
*Calculated based on racemic mixture’s composition.
This compound exhibits 2–3 times greater COX-2 selectivity than the racemate, enhancing anti-inflammatory efficacy . Clinical studies demonstrate that 200 mg this compound provides equivalent or superior pain relief to 400 mg racemic ibuprofen in dental and osteoarthritis pain models .
Pharmacokinetics
- Metabolic Inversion : Racemic ibuprofen’s (R)-enantiomer undergoes 50–60% conversion to this compound, resulting in ~75% total active enantiomer bioavailability .
- Plasma Concentrations : Pure this compound achieves higher plasma levels of the active form compared to racemic administration, reducing interpatient variability .
- Half-life : Both forms share similar half-lives (~2 hours), but this compound avoids the metabolic burden of inverting (R)-enantiomer .
Comparison with Other NSAIDs
Mefenamic Acid
Parameter | This compound | Mefenamic Acid | References |
---|---|---|---|
COX-1 Selectivity | Moderate | High | |
Analgesic Duration | 4–6 hours | 6–8 hours | |
GI Toxicity | Lower | Higher |
Mefenamic acid, a fenamate NSAID, exhibits stronger COX-1 inhibition, increasing GI ulcer risk. This compound’s COX-2 preference offers a safer profile for chronic use .
Naproxen
Parameter | This compound | Naproxen | References |
---|---|---|---|
Half-life | 2 hours | 12–17 hours | |
Cardiovascular Risk | Low | Low | |
Dosing Frequency | 3–4 times/day | 2 times/day |
Naproxen’s prolonged half-life allows less frequent dosing but increases accumulation risk in renal impairment. This compound’s rapid clearance suits acute pain management .
Formulation Advantages
This compound salts, such as (S)-(+)-lysinate and piperazine di-ium bis(S-ibuprofenate), improve aqueous solubility (e.g., 100 mM in DMSO) and bioavailability . These formulations enable intravenous administration, bypassing first-pass metabolism and achieving faster onset .
Clinical and Economic Considerations
Biological Activity
(S)-(+)-Ibuprofen, a widely used nonsteroidal anti-inflammatory drug (NSAID), is primarily recognized for its analgesic, antipyretic, and anti-inflammatory properties. Its biological activity is largely attributed to its ability to inhibit cyclooxygenase (COX) enzymes, which play a crucial role in the synthesis of prostaglandins. This article explores the diverse biological activities of this compound, highlighting recent research findings, case studies, and metabolic pathways involved.
This compound exerts its therapeutic effects primarily through the inhibition of COX-1 and COX-2 enzymes, leading to a reduction in the production of pro-inflammatory prostaglandins. This inhibition not only alleviates pain and inflammation but also affects various physiological processes:
- COX Inhibition : Both COX-1 and COX-2 are rate-determining enzymes in the synthesis of prostaglandins. Inhibition of these enzymes leads to decreased levels of pro-inflammatory mediators such as PGE2 and PGI2, which are implicated in pain signaling and inflammatory responses .
- Metabolic Pathways : Recent studies have shown that this compound influences multiple metabolic pathways beyond COX inhibition. For example, it alters at least 34 different metabolic pathways in liver cells, including those involved in amino acid metabolism and oxidative stress responses .
1. Liver Enzyme Activity
Research has highlighted significant sex-related differences in the biological effects of this compound on liver enzyme activity:
- Male vs. Female Responses : A study demonstrated that ibuprofen treatment caused marked differences in protein expression changes in male and female mice. For instance, it elevated cytochrome P450 activity in females while decreasing it in males, suggesting potential implications for drug metabolism and interactions .
- Oxylipin Profiles : Ibuprofen treatment resulted in altered oxylipin profiles, indicating that it can influence lipid signaling pathways involved in inflammation .
2. Stem Cell Activity
High doses of this compound have been shown to enhance the biological activity of dental pulp stem cells (DPSCs):
- Increased Cell Viability : Studies found that high-dose ibuprofen significantly improved cell viability and reduced DNA damage in DPSCs. This suggests that ibuprofen may enhance regenerative medicine applications by promoting stem cell proliferation and immunophenotype expression .
Case Study 1: Gender Differences in Drug Metabolism
A comprehensive study involving male and female mice illustrated how this compound affects liver metabolism differently based on sex. The findings revealed that:
- Male mice exhibited an increase in specific liver enzymes associated with oxidative stress when treated with ibuprofen.
- In contrast, female mice showed enhanced drug metabolism capabilities due to increased cytochrome P450 activity .
Case Study 2: Ibuprofen's Role in Regenerative Medicine
In a clinical context, researchers evaluated the effects of high-dose ibuprofen on DPSCs:
- Results indicated a significant increase in mitotic activity and proliferation rates among DPSCs treated with ibuprofen compared to control groups.
- These findings support the potential use of ibuprofen as an adjunct therapy in stem cell-based regenerative treatments .
Summary Table of Biological Activities
Properties
IUPAC Name |
(2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid | |
---|---|---|
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
InChI |
InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1 | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
InChI Key |
HEFNNWSXXWATRW-JTQLQIEISA-N | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
Canonical SMILES |
CC(C)CC1=CC=C(C=C1)C(C)C(=O)O | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
Isomeric SMILES |
C[C@@H](C1=CC=C(C=C1)CC(C)C)C(=O)O | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
Molecular Formula |
C13H18O2 | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
DSSTOX Substance ID |
DTXSID9048724 | |
Record name | Dexibuprofen | |
Source | EPA DSSTox | |
URL | https://comptox.epa.gov/dashboard/DTXSID9048724 | |
Description | DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology. | |
Molecular Weight |
206.28 g/mol | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
Solubility |
Insoluble | |
Record name | Dexibuprofen | |
Source | DrugBank | |
URL | https://www.drugbank.ca/drugs/DB09213 | |
Description | The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information. | |
Explanation | Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode) | |
CAS No. |
51146-56-6 | |
Record name | (+)-Ibuprofen | |
Source | CAS Common Chemistry | |
URL | https://commonchemistry.cas.org/detail?cas_rn=51146-56-6 | |
Description | CAS Common Chemistry is an open community resource for accessing chemical information. Nearly 500,000 chemical substances from CAS REGISTRY cover areas of community interest, including common and frequently regulated chemicals, and those relevant to high school and undergraduate chemistry classes. This chemical information, curated by our expert scientists, is provided in alignment with our mission as a division of the American Chemical Society. | |
Explanation | The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated. | |
Record name | Dexibuprofen [USAN:INN:BAN] | |
Source | ChemIDplus | |
URL | https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0051146566 | |
Description | ChemIDplus is a free, web search system that provides access to the structure and nomenclature authority files used for the identification of chemical substances cited in National Library of Medicine (NLM) databases, including the TOXNET system. | |
Record name | Dexibuprofen | |
Source | DrugBank | |
URL | https://www.drugbank.ca/drugs/DB09213 | |
Description | The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information. | |
Explanation | Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode) | |
Record name | DEXIBUPROFEN | |
Source | DTP/NCI | |
URL | https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=759814 | |
Description | The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents. | |
Explanation | Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source. | |
Record name | Dexibuprofen | |
Source | EPA DSSTox | |
URL | https://comptox.epa.gov/dashboard/DTXSID9048724 | |
Description | DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology. | |
Record name | DEXIBUPROFEN | |
Source | FDA Global Substance Registration System (GSRS) | |
URL | https://gsrs.ncats.nih.gov/ginas/app/beta/substances/671DKG7P5S | |
Description | The FDA Global Substance Registration System (GSRS) enables the efficient and accurate exchange of information on what substances are in regulated products. Instead of relying on names, which vary across regulatory domains, countries, and regions, the GSRS knowledge base makes it possible for substances to be defined by standardized, scientific descriptions. | |
Explanation | Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. | |
Melting Point |
49-53 | |
Record name | Dexibuprofen | |
Source | DrugBank | |
URL | https://www.drugbank.ca/drugs/DB09213 | |
Description | The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information. | |
Explanation | Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode) | |
Synthesis routes and methods I
Procedure details
Synthesis routes and methods II
Procedure details
Synthesis routes and methods III
Procedure details
Synthesis routes and methods IV
Procedure details
Retrosynthesis Analysis
AI-Powered Synthesis Planning: Our tool employs the Template_relevance Pistachio, Template_relevance Bkms_metabolic, Template_relevance Pistachio_ringbreaker, Template_relevance Reaxys, Template_relevance Reaxys_biocatalysis model, leveraging a vast database of chemical reactions to predict feasible synthetic routes.
One-Step Synthesis Focus: Specifically designed for one-step synthesis, it provides concise and direct routes for your target compounds, streamlining the synthesis process.
Accurate Predictions: Utilizing the extensive PISTACHIO, BKMS_METABOLIC, PISTACHIO_RINGBREAKER, REAXYS, REAXYS_BIOCATALYSIS database, our tool offers high-accuracy predictions, reflecting the latest in chemical research and data.
Strategy Settings
Precursor scoring | Relevance Heuristic |
---|---|
Min. plausibility | 0.01 |
Model | Template_relevance |
Template Set | Pistachio/Bkms_metabolic/Pistachio_ringbreaker/Reaxys/Reaxys_biocatalysis |
Top-N result to add to graph | 6 |
Feasible Synthetic Routes
Disclaimer and Information on In-Vitro Research Products
Please be aware that all articles and product information presented on BenchChem are intended solely for informational purposes. The products available for purchase on BenchChem are specifically designed for in-vitro studies, which are conducted outside of living organisms. In-vitro studies, derived from the Latin term "in glass," involve experiments performed in controlled laboratory settings using cells or tissues. It is important to note that these products are not categorized as medicines or drugs, and they have not received approval from the FDA for the prevention, treatment, or cure of any medical condition, ailment, or disease. We must emphasize that any form of bodily introduction of these products into humans or animals is strictly prohibited by law. It is essential to adhere to these guidelines to ensure compliance with legal and ethical standards in research and experimentation.